Abstract: Polyurea capsule compositions. A subset of these compositions contain a plurality of capsules and a capsule formation aid, in which each of the capsules contains a polyurea wall and an oil core; the polyurea wall is formed of a reaction product of a polyisocyanate and a cross-linking agent in the presence of the capsule formation aid; and the oil core contains an active material. The polyisocyante, cross-linking agent, and capsule formation aids are described herein. Also disclosed are methods of preparing polyurea capsule compositions, as well as consumer products containing one of these compositions.

Abstract: The invention relates to a cosmetic use of an association of (i) resveratrol or a derivative thereof and (ii) betaine or a derivative thereof, or of a composition containing said association in a physiologically acceptable medium, to fight against the signs of ageing of the skin.

Abstract: A method for producing a coating on skin, the method comprising: A) a step of electrostatically spraying a composition X comprising the following component (a) and the following component (b) directly on the skin to thereby form a coating on a skin surface: (a) one or more volatile substances selected from the group consisting of water, an alcohol, and a ketone, and (b) a polymer having a coating forming ability; and B) a step of applying a composition Y, other than the composition X, containing the following component (c) and the following component (d) to the skin: (c) 5% by mass or more and 20% by mass or less of an adhesive polymer, and (d) 1% by mass or more and 40% by mass or less of a polyol, in this order or in reverse order.

Abstract: A scented deodorizing agent comprising zinc neodecanoate, which is useful to provide a deodorancy benefit and a sustained scent benefit.

Abstract: Disclosed herein is a solid composition for oral care comprising at least one whitening agent chosen from chloride isocyanurate and metal salts of hypochlorite; at least one carbonate base; and optionally at least one effervescent acid. Further disclosed herein is a kit comprising the solid composition and an aqueous liquid composition, as well as methods of whitening teeth and/or producing antibacterial effects in the oral cavity comprising mixing the solid composition with an aqueous liquid composition until the solid composition disintegrates to create a mouthwash comprising hypochlorite; and contacting teeth with the mouthwash comprising hypochlorite.

Abstract: The present invention relates to an oral composition which selectively and effectively removes deposited stains present in the interprismatic space on the tooth enamel surface layer and also effectively prevents new stains from adhering and depositing to thereby provide the beautiful gloss that the teeth inherently have. More specifically, the present invention provide an oral composition which comprises the following ingredient (A) phytic acid or a salt thereof and ingredient (B) tripolyphosphoric acid or a salt thereof, wherein a total content of ingredient (A) in terms of phytic acid and ingredient (B) in terms of acid, and a mass ratio of ingredient (B) in terms of acid to ingredient (A) in terms of phytic acid ((B)/(A)) have specific values, the oral composition comprises (C) a specific polyvalent metal or a salt thereof (C) or comprises ingredient (C) in a molar amount of less than 0.1 times that of ingredient (A) in terms of phytic acid, and has a pH at 25° C. of 5.5 or more and 6.

Abstract: A cosmetic concentrate base composition and cosmetic compositions for use as creams or lotions utilizing the same, the cosmetic concentrate base composition including approximately 20% to 25% by weight of a first component, the first component being a phospholipid component; approximately 10% to 40% by weight of a second component, the second component being a lipid component; and approximately 4% to 5% by weight of a third component, the third component being a hydrophilic component.

Abstract: The present invention relates to rinse-off cleansing compositions comprising a surfactant system, in which the surfactant system comprises an alkyl polyglycoside and an acyl glutamate present in specific amounts, for providing compositions that are not only mild on the skin and/or eyes that are stable especially under acidic pH conditions, but also have simpler formulations which have fewer ingredients, good rinse-off property, and preferably more cost effective.

Abstract: In an exemplary embodiment there is presented a formulation that is topically applied to the outer jawline and neck skin to improve the appearance of the skin by repairing or concealing age-related skin effects, such as wrinkles, improving skin tone by reducing stretching and sagging of the skin, adding moisture to reduce skin dryness, and adding an appearance of brightness. An exemplary embodiment of the formulation includes a blend of oligosaccharides, medium chain triglycerides, peptides, silanol, and diglucosyl gallic acid, all provided in a viscous liquid emulsion base for ease of dispensing from a pump dispenser.

Abstract: A peptide has the formula (I) R1—Wm—Xn-AA1-AA2-AA3-Yp—Zq—R2, where AA1 is Tyr or Trp, AA2 is Val, Ile, Leu or Met, AA3 is Tyr, Phe or Trp, W, X, Y and Z are amino acids, m, n, p and q are each 0 or 1, and m+n+p+q is less than or equal to 2. R1 is H, a polymer derived from polyethylene glycol, a non-cyclic aliphatic group, alicyclyl, heterocyclyl, heteroarylalkyl, aryl, aralkyl, or R5—CO—. R5 is H, a non-cyclic aliphatic group, alicyclyl, aryl, aralkyl, heterocyclyl or heteroarylalkyl. R2 is —NR3R4, —OR3, or —SR3. R3 and R4 are each H, a polymer derived from polyethylene glycol, a non-cyclic aliphatic group, alicyclyl, heterocyclyl, heteroarylalkyl, aryl, or aralkyl. R1 and R2 are not amino acids. Cosmetic or pharmaceutical compositions may include the peptide. It find use in reduction of lipid accumulation in the skin, treatment of cellulite, and treatment of symptoms of skin aging.

Abstract: The present invention teaches a hair straightening system including formulations that will safely and effectively straighten curly hair for at least 2-3 months after a single application, despite frequent washings of the hair. Methods for obtaining said formulations are disclosed. Hair straightening systems including shampoo and one or more conditioners are also provided.

Abstract: A composition including a synergistic combination of a vitamin D3 or a derivative or precursor thereof and hyaluronic acid or derivate thereof encapsulated in a lipid based colloidal carrier system (preferably lipid based vesicles such as liposomes, niosomes, tranferosomes) and topical formulations thereof, as well as their use in the prevention and/or treatment of inflamed skin and mucous membrane, especially in the prevention and/or treatment of skin photodamage, in particular in the prevention and/or treatment of skin erythema (skin inflammation) and actinic keratosis, as well non melanoma skin cancer.

Abstract: Disclosed is a personal care composition comprising (a) particle comprising chitosan salt at the outer surface of the particle; and (b) functionalized non-volatile silicone, wherein the amount of the functionalized non-volatile silicone is greater than 20% by weight of the total non-volatile silicone.

Abstract: A whitening composition, an oral care product including the whitening composition, and a method for whitening teeth are disclosed. The whitening composition may include an anhydrous component and an aqueous component. The anhydrous component may include a base gel and a chloroisocyanurate. The chloroisocyanurate may be present in the anhydrous component in an amount of from about 0.01 weight % to about 30 weight %, based on a totally weight of the anhydrous component. The anhydrous component may include water.

Abstract: A topical composition for treating age spots and wrinkles includes at least one first skin-whitening agent, at least one wrinkle-reducing agent, and a pharmaceutically or cosmetically acceptable solvent. In a preferred embodiment, the composition includes two whitening agents and two wrinkle-reducing agents. The skin-whitening agents include a tyrosinase-inhibiting glycosylated hydroquinone and a blend of alpine plant-based extracts. The wrinkle-reducing agents include avian egg extract and stabilized vitamin C.

Abstract: The invention relates to a moisturizing cosmetic composition comprising: (A) 30-99 wt % of birch sap, (B) 0.001-5 wt % of hydrolyzed sodium hyaluronate, and (C) optionally, ingredients commonly used in skincare cosmetics, wherein the moisturizing cosmetic composition of the invention does not comprise water typically added as a separate component.

Abstract: A kit for mucosally administering a metastable supersaturated solution of a pharmaceutical active agent to a human patient includes a first compartment comprising a first composition comprising a pharmaceutical active agent in solution at or below equilibrium solubility, and a second composition comprising an acidic buffer. The first and second compartments maintain separation of the first and second compositions during storage, and allow for mixing of the first and second compositions to form a supersaturated solution above equilibrium solubility of the pharmaceutical active agent for immediate mucosal administration to a human patient. In one embodiment, the second composition comprises an acidic buffer and the supersaturated solution has an acidic pH. Alternatively, the second composition comprises a basic buffer and the supersaturated solution has a basic pH.

Abstract: This invention teaches a system and a method to control the dispensing of swallow able medicine at the desired flow rate and in the desired location of the gastro-intestinal tract.

Abstract: Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.

Abstract: The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.

Abstract: The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a diffusion-controlled inner coating and an enteric outer coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.

Abstract: There is provided a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form includes at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit including the same are also provided.

Abstract: The invention relates to a Pharmaceutical composition of a puff of a spray or inhaler for use in the treatment of sinusitis or/and COPD, by administration by inhalation to a human subject comprising at least one topical corticoid, a sugar alcohol, and an antiseptic wherein said topical corticoid is present in an amount between 10 and 1000 ?g, the sugar alcohol being present in a percentage between 0.1 and 20, and the antiseptic present in a percentage between 0.001 and 5. This composition can be administered by nasal spray or dry powder inhaler and is used for treating the upper and lower respiratory tract, in particular sinusitis with or without polyps, as well as COPD or other respiratory deceases as mucoviscidosis.

Abstract: The present invention includes systems, methods and compositions related to the production and use of chemically modified cannabinoid food and beverage additives having enhanced water solubility and stability.

Abstract: Nano-crystallized herbal ingredient-containing package for use in a food processor or being used directly to prepare an herbal decoction is provided. The nano-crystallized herbal ingredient-containing package comprises a housing; single or multiple herbal ingredient nano-crystals; one or more non-additive and anti-caking spacers for preventing from caking to block solvent flowing through the package towards said single or multiple herbal ingredient nano-crystals during processing by the food processor; and optionally one or more stabilizing agents for stabilizing said single or multiple herbal ingredient nano-crystals during nano-crystallization of the herbal ingredients and during preparation of said herbal decoction. A method of preparing a herbal decoction from the said package is also provided.

Abstract: The invention refers to a product made of liposomes which comprises lactoferrin and a component selected from hyaluronic acid or chitosan, as active ingredients, as well as to compositions comprising it and their use in the prevention and/or treatment of diseases related to the eye, such as for example the ocular diseases characterized by the presence of an inflammatory condition.

Abstract: Compositions for the immediate release, extended release, or sustained release of two or more active agents, in which the two or more active agents comprises at least one cannabinoid and at least one non-cannabinoid therapeutic agent. The compositions comprise a population of particles, in which each particles comprises the at least one cannabinoid, the at least one non-cannabinoid therapeutic agent, or a combination thereof.

Abstract: Compositions for the extended release of one or more cannabinoids, in which the compositions comprise a population of particles. Each particle may comprise the one or more cannabinoids, one or more drug-releasing agents, and a core. The APIs may be a cannabinoid, such as cannabidiol or ?9-tetrahydrocannabinol. The core may comprise an inert material. The one or more cannabinoids may comprise ?9-tetrahydrocannabinol, cannabidiol, or a combination thereof.

Abstract: A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component.

Abstract: The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject.

Abstract: Materials and methods for preparing a payload-containing microcapsule with walls that have hexahydrotriazine (HT) and/or hemiaminal (HA) structures are disclosed. To an HT small molecule or a HA small molecule, or a combination thereof, in a solvent is added a cross-linking agent, NH4Cl, and a copolymer. The solution is acidified, and a payload agent is added. The HT small molecule and HA small molecule may have orthogonal functionality.

Abstract: The present invention relates to an exosome-based nanoparticle composite and a method for preparing the same. More specifically, the present invention relates to an exosome-based nanoparticle composite that uses exosomes isolated from cells and a biocompatible polymer to achieve improved in vivo stability and redispersibility, and a method for preparing the nanoparticle composite. The nanoparticle composite of the present invention exhibits a stable and continuous drug release pattern irrespective of the solubility of the drug and has excellent tumor targeting due to its good in vivo stability and improved redispersibility in aqueous solution.

Abstract: The present invention relates to polymeric nanoparticles comprising salinomycin and methods for treating certain diseases comprising administering these polymeric nanoparticles to a subject in need thereof.

Abstract: The present invention relates to storage-stable formulations of 3-nitrooxypropanol and derivatives thereof as well as to the production of such formulations.

Abstract: The invention relates to Bis-thiol compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating, managing or lessening the severity of pulmonary infections in a subject, the method comprising administering to the subject a bismuth-thiol (BT) composition that comprises at least one BT compound.

Abstract: A composition for treatment of inflammation in a mammal is provided. The mammal has a neutrophil to lymphocyte ratio (NLR). The composition includes a curcumagalactomannoside and a hops extract. The curcumagalactomannoside and the hops extract cooperate to decrease the NLR of the mammal 12 weeks after ingestion of the composition. A method of treatment of inflammation in a mammal is also provided. The method includes obtaining a parameter of the mammal. The method further includes dosing the composition based on the parameter. The method further includes administering the composition to the mammal.

Abstract: The present invention includes a composition and method for treating a glioblastoma in a human or animal subject comprising the steps of: identifying the human or animal subject in need of treatment of a glioblastoma, wherein the human or animal is no longer responsive to at least one of chemotherapy, surgery, or radiation therapy; and administering to the human or animal subject a therapeutically effective amount of a composition comprising: an amount of a curcumin or curcuminoids in one or more liposomes, or curcumin or curcuminoids and empty liposomes and administered prior to, concomitantly, or after administration of the curcumin or curcuminoids, that is effective for treating the glioblastoma, wherein the liposomal curcumin or curcuminoids, or empty liposomes, eliminate the QT prolongation caused by the curcumin or curcuminoids; and at least one chemotherapeutic agent that is synergistic with curcumin to treat the glioblastoma.

Abstract: Compositions and methods are provided for the prevention and treatment of chronic wounds such as pressure ulcers by transdermal delivery of an agent that increases activity of HIF-1alpha in the wound. Wound healing ability reduced in aged subjects can be restored by use of the iron chelator formulations and methods to be similar to that of young subjects.

Abstract: A method for treating cancer in a subject is provided; the method includes administrating bupropion to the subject, wherein the tumor cells of the cancer overexpress neuronal acetylcholine receptor subunit ?9 (CHRNA9). Another method for treating cancer in a subject is provided; the method includes administrating a pharmaceutical composition to the subject, wherein the pharmaceutical composition includes: a therapeutically effective amount of bupropion and a pharmaceutically acceptable excipient; wherein the tumor cells of the cancer overexpress CHRNA9. A method for inhibiting migration of tumor cells is also provided; the method includes administrating an effective amount of bupropion to the tumor cells; wherein the tumor cells overexpress CHRNA9.

Abstract: Disclosed herein are methods of treating one or more tumors by administering to the subject a therapeutically effective amount of a combination of RAD1901 or solvates (e.g., hydrate) or salts thereof and one or more second therapeutic agent(s) (e.g., everolimus). The cancer is an estrogen-dependent cancer, such as breast cancer, ovarian cancer, colon cancer, endometrial cancer, or prostate cancer.

Abstract: The invention provides stable, aqueous capsaicin injectable formulations, a unit dose containing such injectable formulations, medical kits, and methods for using such injectable formulations and unit doses to treat patients suffering from pain, such as osteoarthritic knee pain. The stable, aqueous capsaicin injectable formulations may contain, for example, capsaicin, a solubilizing agent (e.g., a polyethylene glycol ester of a (C15-C25) hydroxyalkanoic acid), an antioxidant, and water.

Abstract: A method is disclosed of treating pain with senicapoc, a potent Ca2+-activated K+ channel, KCa3.1 antagonist in CNS-resident microglia. Senicapoc is shown to cause in a decrease of IL-1? and NO release from microglia cells vivo and in vitro. Because of contribution of KCa3.1 to neuropathological processes, senicapoc is useful in the treatment of chronic, neuropathic, visceral, and inflammatory pain and the reversal of tactile allodynia.

Abstract: The present disclosure relates to a pharmaceutical composition for inducing an exercise mimetic effect, which contains an ?1-adrenergic receptor agonist as an active ingredient, and a method for screening a drug for inducing an exercise mimetic effect using the ?1-adrenergic receptor agonist. The ?1-adrenergic receptor agonist of the present disclosure increases the expression of p-AMPK, PPAR? and PGC-1?, which play key roles in maintaining and regulating energy metabolic activity in vivo, thereby increasing glucose uptake into skeletal muscle cells, suppressing adipocyte differentiation and lipid accumulation, reducing abdominal fat and body weight as well as regulating mitochondrial metabolic disorders and suppressing inflammatory responses. Accordingly, the ?1-adrenergic receptor agonist can be usefully used to prevent and treat diseases requiring AMPK activation (metabolic diseases, cardiovascular diseases, inflammatory disease, etc.).

Abstract: A method of protecting a host from an enteric toxigenic pathogen comprises administering a salicylanilide to the host. A method of reducing virulence of an enteric toxigenic pathogen comprises administering a salicylanilide to a host infected with or at risk of infection with pathogen. A method of reducing recurrence of an infection caused by an enteric toxigenic pathogen, comprises administering a salicylanilide to a host previously infected with the pathogen.

Abstract: A method of attenuating, treating or preventing cognitive aging in an individual who does not have dementia includes administering to the individual a therapeutically effective amount of a composition containing an omega-3 fatty acid and choline. The method can achieve a benefit that is one or more of decreasing brain atrophy, increasing or maintaining number of synapses, increasing amyloid-? phagocytosis, or decreasing or maintaining neuroinflammation in the non-demented individual. The method can prevent dementia in an individual at risk thereof, for example an elderly human. The composition can be administered to the individual in a daily dose that provides 5.5 mg/day to 5,500 mg/day of the choline, for example 85 mg/day to 3,500 mg/day of the choline.

Abstract: The present subject matter includes novel chemical formulations having antimicrobial, antifungal, antiseptic, and related effect in a wide range of applications for treating or preventing infections as well as treating various surfaces that may become tainted with infectants. In some embodiments, the formulation includes isoamyl hexanoates and at least one of propanoic and/or isobutyric acid.

Abstract: This invention relates to a naproxen formulation suitable for encapsulation into a soft gel dosage unit by increasing the stability, concentration, and bioavailability of naproxen. Fill formulations of the invention may include other active pharmaceutical ingredients and combinations of two or more active pharmaceutical ingredients. This invention also provides for adjusting pH values of fill formulations without additional process steps. A process for increasing the achievable concentration of an active NSAID pharmaceutical ingredient, such as naproxen, relative to fill composition for dosage units is also provided. The highly concentrated formulation of this invention permits a reduction in the fill volume or dosage unit size, or an increase in concentration of the active pharmaceutical ingredient per dosage form. The invention also relates to a formulation of optimal stability suitable for supporting a fill composition compatible with the soft gel dosage unit.

Abstract: In an embodiment, a method to enhance a non-surgical medical treatment, the method including applying a composition having an antifibrinolytic agent to an area of skin for non-surgical medical treatment, where the applying is at least one of before, during, and after the non-surgical medical treatment, beginning the non-surgical medical treatment to the area of skin, and continuing the non-surgical medical treatment until the non-surgical medical treatment is completed. In some embodiments, the antifibrinolytic agent is tranexamic acid in an amount of about 20% (w/v). In some embodiments, the method further includes minimizing, by the antifibrinolytic agent, bruising caused by the non-surgical medical treatment. In an additional embodiment, the present disclosure relates to a composition to enhance a non-surgical medical treatment, the composition having an antifibrinolytic agent. In a further embodiment, the present disclosure relates to a kit having a carrier and an antifibrinolytic agent.

Abstract: The present invention discloses a processes for the preparation of a stable liquid pharmaceutical composition comprising levothyroxine or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients wherein the liquid composition of the present invention is used for oral administration. The present invention also discloses stable liquid compositions comprising levothyroxine or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients prepared according to the processes of the present invention.

Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.